The Online Investor
Pozen Inc. (POZN)

Pozen is a pharmaceutical company. Co. has developed VIMOVO® with AstraZeneca AB. VIMOVO has been approved by the FDA for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drug-associated gastric ulcers. Co.'s PA product candidates contain a combination of a proton pump inhibitor and enteric coated aspirin in a single tablet. Co.'s product candidates include PA32540 for the secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, and PA8140, a low dose version of PA32540.
Company Name: 
Pozen Inc.
Website: 
www.pozen.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree POZN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Pozen Inc. (POZN) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.